{"ModuleTitle": "Company Description", "CompanyName": "Cortexyme, Inc.", "Symbol": "CRTX", "Address": "269 EAST GRAND AVE, SOUTH SAN FRANCISCO, California, 94080, United States of America", "Phone": "415-910-5717", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a clinical stage biopharmaceutical company pioneering a novel\r\ndisease-modifying therapeutic approach to treat what we believe to be a key\r\nunderlying cause of Alzheimer's and other degenerative diseases. Our approach is\r\nbased on the seminal discovery of the presence of Porphyromonas gingivalis,\r\nor P. gingivalis, and its secreted toxic virulence factor proteases, called\r\ngingipains, in the brains of greater than 90% of more than 100 Alzheimer's\r\npatients observed across multiple studies to date. Additionally, we have\r\nobserved that P. gingivalis infection causes Alzheimer's pathology in animal\r\nmodels, and these effects have been successfully treated with a gingipain\r\ninhibitor in preclinical studies. Our proprietary lead drug candidate, COR388,\r\nis an orally administered, brain-penetrating small molecule gingipain inhibitor.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f16%2f0001564590-20-011165.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Casey Crawford Lynch", "title": "Chairman, President & Chief Executive Officer"}, {"name": "Christopher P. Lowe", "title": "CFO, Treasurer & Principal Accounting Officer"}, {"name": "Leslie J. Holsinger", "title": "Executive Vice President-Research & Development"}, {"name": "Michael J. Detke", "title": "Chief Medical Officer"}, {"name": "Stephen S. Dominy", "title": "Chief Scientific Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}